-
41.发明公开公开(公告)号：US20230374105A1
公开(公告)日：2023-11-23
申请号：US18339565
申请日：2023-06-22
发明人： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC分类号： C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： C07K14/70596 , C07K14/7051 , C07K16/2803 , C07K16/2866 , A61K45/06 , A61K39/001112 , A61K39/001113 , A61K39/001124 , C07K2317/24 , C07K2317/622 , C07K2319/00 , A61K2039/5156 , A61K2039/5158 , A61K2039/70 , A61K38/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
公开(公告)号：US20230026049A1
公开(公告)日：2023-01-26
申请号：US17661207
申请日：2022-04-28
发明人： Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C07K14/74 , C12N9/90 , C12N9/12 , C07K14/71 , A61K31/436 , A61K35/17
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：US20230000964A1
公开(公告)日：2023-01-05
申请号：US17811606
申请日：2022-07-11
申请人： Novartis AG , The Trustees of the University of Pennsylvania , Dana-Farber Cancer Institute, Inc. , President and Fellows of Harvard College
发明人： Jennifer Brogdon , Hwai Wen Chang , Boris Engels , Gordon James Freeman , Gerhard Johann Frey , Jennifer Marie Mataraza , Reshma Singh , Arlene Helen Sharpe
IPC分类号： A61K39/00 , A61P35/00 , A61K39/395 , A61K45/06
摘要： Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
-
44.发明授权公开(公告)号：US11459390B2
公开(公告)日：2022-10-04
申请号：US15543688
申请日：2016-01-15
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , David Glass , Thomas Huber , Julia Jascur , Carl H. June , Jihyun Lee , Joan Mannick , Michael C. Milone , Leon Murphy , Avery D. Posey , Huijuan Song , Yongqiang Wang , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , A61K35/17 , C07K16/30 , A61P35/00 , A61P35/02 , A61K48/00 , C12N15/86 , A61K35/12
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
-
公开(公告)号：US20220195010A1
公开(公告)日：2022-06-23
申请号：US17464528
申请日：2021-09-01
发明人： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC分类号： C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
公开(公告)号：US20210396739A1
公开(公告)日：2021-12-23
申请号：US17052051
申请日：2019-05-01
发明人： Iulian Pruteanu-Malinici , Jennifer Brogdon , Elena Orlando , Jan J. Melenhorst , Joseph A. Fraietta
IPC分类号： G01N33/50 , G01N33/574 , G01N33/68
摘要： The invention provides biomarkers, e.g, cancer biomarkers, and methods of using said biomarkers. Specifically, the invention provides biomarkers for use, e.g., in evaluating CAR-T cell therapies and predicting clinical outcome.
-
公开(公告)号：US10927184B2
公开(公告)日：2021-02-23
申请号：US16192375
申请日：2018-11-15
发明人： Jennifer Brogdon , Carl H. June , Andreas Loew , Marcela Maus , John Scholler
IPC分类号： C07K16/28 , C07K16/30 , C07K14/725 , C07K14/705 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
-
公开(公告)号：US20200215171A1
公开(公告)日：2020-07-09
申请号：US16728557
申请日：2019-12-27
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , Saar Gill , David Jonathan Glass , Julia Jascur , Saad Kenderian , Joan Mannick , Michael C. Milone , Leon Murphy , Celeste Richardson , Reshma Singh , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： A61K39/00 , C07K14/725 , C07K16/28 , A61K35/17 , A61K31/7068 , A61K45/06 , C07K14/705
摘要： The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
-
公开(公告)号：US10703819B2
公开(公告)日：2020-07-07
申请号：US15726703
申请日：2017-10-06
发明人： Jennifer Brogdon , Saar Gill , David Jonathan Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , A61K39/00 , C07K16/24 , C12N5/0783
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
公开(公告)号：US10568947B2
公开(公告)日：2020-02-25
申请号：US14805075
申请日：2015-07-21
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , Saar Gill , David Glass , Julia Jascur , Saad Kenderian , Joan Mannick , Michael C. Milone , Leon Murphy , Celeste Richardson , Reshma Singh , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： A61K39/00 , C07K14/725 , C07K16/28 , A61K31/7068 , C07K14/705 , A61K45/06
摘要： The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
-
-
-
-
-
-
-
-
-
搜索结果
60 条记录 (耗时 0.048 秒)
